secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001104659-23-011256
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health and SynWorld Mutually Terminate License Agreement for Canalevia in Dogs in China
--------------------------------------------------------------------------------

- Jaguar Health (NASDAQ:JAGX) and SynWorld Technologies terminated the exclusive license agreement for Canalevia (crofelemer) to treat diarrhea in dogs in China, effective January 31, 2023.
- Termination is driven by Jaguar's 2023 strategic focus on human drug development, including Phase 3 OnTarget trial for cancer therapy-related diarrhea.
- SynWorld's General Manager Tao Wang, a long-term shareholder of restricted Jaguar stock, fully supports the mutual termination decision.
- All licenses granted to SynWorld under the agreement were revoked, and rights reverted back to Jaguar.
- Jaguar expects enrollment in the OnTarget trial to complete in Q2 2023; also prioritizing proof-of-concept trial for short bowel syndrome and congenital diarrheal disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/0001104659-23-011256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923011256/tm235360d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-011256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer